FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease
February 16, 2016 07:20 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 16, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the American Journal of Kidney Disease...